-
British Medical Journal Jan 1973
Topics: Drug Interactions; Humans; Methyldopa; Phenobarbital
PubMed: 4683647
DOI: 10.1136/bmj.1.5844.49-a -
Neuropsychobiology 1976In a double-blind, controlled clinical study, lasting 8 weeks, 55 hospitalized schizophrenic patients were randomly assigned to one of the five drug treatments: 600 mg... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
In a double-blind, controlled clinical study, lasting 8 weeks, 55 hospitalized schizophrenic patients were randomly assigned to one of the five drug treatments: 600 mg chlorpromazine/day, 300 mg chlorpromazine/day, 300 mg chlorpromazine--250 mg alpha-methyldopa/day, 300 mg chlorpromazine--500 mg alpha-methyldopa/day, 300 mg chlorpromazine--750 mg alpha-methyldopa/day. The results showed that all five treatments were significantly effective in treating schizophrenic behavior. The dose-response relationship for the different doses of alpha-methyldopa in combination with chlorpromazine, suggested an optimal response to 300 mg chlorpromazine--500 mg alpha-methyldopa.
Topics: Adult; Blood Pressure; Chlorpromazine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Methyldopa; Middle Aged; Placebos; Schizophrenia
PubMed: 796755
DOI: 10.1159/000117539 -
Archives of Internal Medicine Feb 1979Though drug fever from methyldopa is well known, to my knowledge fever and hypotension simulating septic shock have never been described in this country as a syndrome...
Though drug fever from methyldopa is well known, to my knowledge fever and hypotension simulating septic shock have never been described in this country as a syndrome resulting from methyldopa therapy. Three such cases are presented here, all proved on rechallenge. They erroneously accounted for almost 6% of all cases of septic shock at St Elizabeth Medical Center in the last ten years.
Topics: Aged; Diagnosis, Differential; Female; Fever; Humans; Hypotension; Methyldopa; Shock, Septic
PubMed: 434973
DOI: No ID Found -
Lancet (London, England) Jun 1973
Clinical Trial Comparative Study
Topics: Carbidopa; Dihydroxyphenylalanine; Drug Synergism; Humans; Hydrazines; Methyldopa; Parkinson Disease
PubMed: 4122619
DOI: 10.1016/s0140-6736(73)90586-2 -
Lancet (London, England) Aug 1976
Topics: Chemical and Drug Induced Liver Injury; Humans; Methyldopa
PubMed: 59868
DOI: No ID Found -
JAMA Apr 1977Five patients with hypertension died as a result of myocarditis. Three were treated with methyldopa and hydrochlorothiazide, two with methyldopa alone. Their ages ranged...
Five patients with hypertension died as a result of myocarditis. Three were treated with methyldopa and hydrochlorothiazide, two with methyldopa alone. Their ages ranged from 30 to 71 years. In all instances death occurred suddenly, and myocarditis was not suspected clinically. The inflammatory changes in the hearts of these patients were most consistent with a hypersensitivity reaction. Additionally, there was hepatitis consistent with hypersensitivity in four of the cases.
Topics: Adult; Aged; Death, Sudden; Drug Hypersensitivity; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Methyldopa; Middle Aged; Myocarditis; Myocardium
PubMed: 576672
DOI: No ID Found -
Clinical Pharmacology and Therapeutics Apr 1988This study examined the effect of two widely used iron treatments on methyldopa absorption, metabolism, and blood pressure control. A 500 mg tablet of methyldopa (2.37... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
This study examined the effect of two widely used iron treatments on methyldopa absorption, metabolism, and blood pressure control. A 500 mg tablet of methyldopa (2.37 mmol) was taken with and without ferrous sulfate (325 mg) by 12 normal subjects in a randomized crossover trial. When ferrous sulfate was taken with methyldopa there was a decrease in the proportion of methyldopa excreted as "free" methyldopa (49.5% +/- 12.4% vs 21.1% +/- 4.77%; p less than 0.01), a significant increase in the proportion excreted as methyldopa sulfate (37.8% +/- 12.3% vs 65.8% +/- 10.5%; p less than 0.01), and a decrease in the percentage of methyldopa absorbed (29.1% +/- 12.5% vs 7.88% +/- 4.14%; p less than 0.01). These factors resulted in an 88% reduction in the quantity of "free" methyldopa excreted. To determine if an iron preparation without sulfate produced the same effect, the study was repeated with ferrous gluconate (600 mg) with similar results. The clinical consequences of the methyldopa-ferrous sulfate interaction was determined in five hypertensive subjects receiving chronic methyldopa therapy. The subjects took ferrous sulfate for 2 weeks. There was an increase in both systolic and diastolic blood pressure in four patients and a decrease in blood pressure in all patients after ferrous sulfate was discontinued. The increases in blood pressure were substantial in three of the patients.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Drug Interactions; Female; Ferrous Compounds; Humans; Hypertension; Intestinal Absorption; Male; Methyldopa; Random Allocation
PubMed: 3356082
DOI: 10.1038/clpt.1988.47 -
Clinical Pharmacology and Therapeutics Oct 1977Eighteen patients with hypertension participated in a double-blind, randomized study to evaluate the effect of trimazosin, methyldopa, and placebo on supine and standing... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
Eighteen patients with hypertension participated in a double-blind, randomized study to evaluate the effect of trimazosin, methyldopa, and placebo on supine and standing blood pressure and heart rate. Of 6 patients on methyldopa, one developed drug fever (and was dropped from the study) and one developed impotence. None of 6 patients on trimazosin and none of 6 patients on placebo developed any adverse effects. The mean supine blood pressure on 900 mg trimazosin daily was 17.0/12.8 mm Hg lower than that on the first placebo trial (p less than 0.01) and 17.0/12.1 mm Hg lower than that on the second placebo trial (p less than 0.01). The mean supine blood pressure on 2,250 mg methyldopa daily was 17.8/12.4 mm Hg lower than that on the first placebo trial (p less than 0.01) and 16.8/13.0 mm Hg lower than that on the second placebo trial (p less than 0.01). The mean supine blood pressure was not significantly affected by placebo. Trimazosin, 900 mg daily, and methyldopa, 2,250 mg daily, were equally effective in lowering supine and standing systolic and diastolic blood pressure and did not affect supine or standing heart rate.
Topics: Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Heart Rate; Humans; Hypertension; Male; Methyldopa; Middle Aged; Piperazines; Placebos; Quinazolines; Vasodilator Agents
PubMed: 332438
DOI: 10.1002/cpt1977224425 -
Clinical and Experimental Pharmacology... 19781. The hypotensive effect of methyldopa alone or associated with other hypotensive drugs was evaluated in 155 patients. After 10 days of treatment, the blood pressure... (Clinical Trial)
Clinical Trial
1. The hypotensive effect of methyldopa alone or associated with other hypotensive drugs was evaluated in 155 patients. After 10 days of treatment, the blood pressure was back to normal in 80% and in 50% of the patients with mild and moderate hypertension, and it was significantly decreased in those with severe hypertension. 2. Contrary to other hypotensive drugs, it did not produce a significant increase in BUN and serum creatinine. Occasional or recurrent episodes of orthostatic hypotension were observed in about 18% of the cases, but in none did it produce important symptoms of cerebral or myocardial ischaemia.
Topics: Blood Pressure; Blood Urea Nitrogen; Clinical Trials as Topic; Creatinine; Humans; Hypertension; Kidney; Methyldopa
PubMed: 354829
DOI: No ID Found -
The Journal of Pharmacology and... Aug 1976Single doses of methyldopa were administered orally and intravenously as aqueous solutions to 12 healthy volunteers in a crossover study. Serial plasma and urine samples... (Clinical Trial)
Clinical Trial
Single doses of methyldopa were administered orally and intravenously as aqueous solutions to 12 healthy volunteers in a crossover study. Serial plasma and urine samples were analyzed specifically for methyldopa and its O-sulfate conjugate. Kinetic analyses of the results indicated that methyldopa disposition could be adequately represented by a two-compartment open model. Renal excretion accounted for about two-thirds of the plasma clearance of methylodopa. Absorption profiles were constructed with the aid of the pharmacokinetic model and contrasted with estimates of absorption which were model-independent. The mean fraction reaching the systemic circulation as methyldopa was estimated to be 0.25 (range 0.08-0.62 for n = 11). Although most of the absorption occurred within the first 5 hours oral administration, a minor component, suggestive of limited enterohepatic circulation, persisted from 9 to 36 hours. O-sulfate conjugation was route-dependent and appeared to be derived predominantly, if not exclusively, as a first-pass effect of absorption and/or enterophepatic circulation.
Topics: Administration, Oral; Biopharmaceutics; Clinical Trials as Topic; Enterohepatic Circulation; Half-Life; Humans; Injections, Intravenous; Intestinal Absorption; Kinetics; Male; Methyldopa; Models, Biological; Time Factors
PubMed: 781212
DOI: No ID Found